Press Releases Archives - Neurogastrx, Inc.

07 Nov Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating  Significant Reductions in Nausea and Vomiting Induced by  GLP-1 Receptor Agonist Semaglutide

Posted at 00:00h in Press Releases

Results, presented at ObesityWeek® 2025, showed patients receiving NG101 saw 40% reduction in nausea incidence and 67% reduction in vomiting incidence Only 30% of patients who start GLP-1s for weight loss are still using them after one year, with GI side effects cited as the #1...

07 Oct Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®

Posted at 00:00h in Press Releases

Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing Achievement of Proven Long-Term Benefits WOBURN, MA, October 7, 2025 – Neurogastrx, Inc., today announced that it will share proof-of-concept data from the clinical study of NG101 (metopimazine...

16 Oct Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication

Posted at 05:00h in Press Releases

NG101 Significantly Reduced Incidence of Nausea by 40% and Frequency of Vomiting by 56% without Changing the Safety Profile of the GLP-1 Agonist WOBURN, MA, October 16, 2024 – Neurogastrx, Inc. today announced positive topline results from a new study of NG101 (metopimazine mesylate) showing...

26 Aug Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

Posted at 06:30h in Press Releases

Woburn, MA – August 26, 2021 – Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital. Other new investors participating in the...

04 Jan Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept

Posted at 10:56h in Press Releases

- JIM O'MARA NAMED CHIEF EXECUTIVE OFFICER - BOSTON, Jan. 4, 2018 /PRNewswire/ -- Neurogastrx, Inc., a private biopharmaceutical company focused on discovering and developing therapies for gastrointestinal disorders affecting the enteric nervous system, today announced a transformative $45M Series A financing co-led by 5AM Ventures, OrbiMed Advisors and venBio Partners. The funds will...

Press Releases

07 Nov Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating  Significant Reductions in Nausea and Vomiting Induced by  GLP-1 Receptor Agonist Semaglutide

07 Oct Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®

16 Oct Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication

26 Aug Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

04 Jan Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept

Contact Us

Privacy Policy

Press Releases

07 Nov Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

07 Oct Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®

16 Oct Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication

26 Aug Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders

04 Jan Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept

Contact Us

Privacy Policy

07 Nov Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating  Significant Reductions in Nausea and Vomiting Induced by  GLP-1 Receptor Agonist Semaglutide